


(NAMs)

AI



2025 4 FDA
AI NAMs NAMs NAMs AI


New Approach Methodologies, NAMs

NAMs NAMs AI
(in vitro) (ex vivo) (in silico)


• 3D Organ-on-Chip MPS Organoid

• PBPK QSP QST

/



NAMs



AI

AI

Target-to-hit Hit-to-lead Lead-to-PCC




MEDICILON

ROS


STEP

HepG

3D -HepG2



3D -HepG2





CDE 2020




CRA

IND





ABT-263	24	CTG	ADP	5	anti-CD42	anti-CD62P
ABT-263			ADP			
CD62P+ cells						



Smarca2/4 PROTAC	MV-4-11	(DMSO, 10 nM, 100 nM),	A	B	PROTAC	10nM
Smarca2	Smarca4	100nM				

PDXO - HER2 EGFR

PDXO HER2 : &

